Sandbox/AL: Difference between revisions

Revision as of 17:50, 7 July 2014

Reteplase
Retavase^® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Reteplase
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

For patient information, click here. Synonyms / Brand Names: Retavase^®

Overview

Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.^{[citation needed]}

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

Reteplase was approved by the Food and Drug Administration in 1996.

FDA Package Insert

Retavase^®

Mechanism of Action

Retavase® is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in fibrinogen levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.^[1]

References

↑ "RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.]".

[dailymed.nlm.nih.gov-1] "RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.]".

[1]

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Fondaparinux}}
+{{Reteplase}}
 {{CMG}}; {{AE}} {{AZ}}
-'''''For patient information, click <u>[[Fondaparinux (patient information)|here]]'''''</u>.
-{{SB}} Arixtra<sup>®</sup>
+'''''For patient information, click <u>[[Reteplase (patient information)|here]]'''''</u>.
+{{SB}} Retavase<sup>®</sup>
 ==Overview==
-'''Fondaparinux''' (trade name '''Arixtra''') is an [[anticoagulant]] medication chemically related to [[low molecular weight heparin]]s. It is marketed by [[GlaxoSmithKline]]. A generic version developed by Alchemia is marketed within the US by [[Dr. Reddy's Laboratories]].
+'''Reteplase''' (trade names '''Retavase''', '''Rapilysin''') is a [[thrombolytic drug]], used to treat [[myocardial infarction|heart attacks]] by breaking up the [[clot]]s that cause them.
+Reteplase is a recombinant non-glycosylated form of human [[tissue plasminogen activator]], which has been modified to contain 357 of the 527 [[amino acid]]s of the original [[protein]]. It is produced in the [[bacterium]] [[Escherichia coli]].{{citation needed|date=December 2013}}
+Reteplase is similar to recombinant human tissue plasminogen activator ([[alteplase]]), but the modifications give reteplase a longer [[half-life]] of 13–16 minutes.  Reteplase also binds [[fibrin]] with lower affinity than alteplase, improving its ability to penetrate into clots.
+Reteplase was approved by the [[Food and Drug Administration]] in 1996.
 ==Category==
-[[Factor Xa]] inhibitors.
+[[Thrombolytics]], tissue plasminogen activators.
 ==FDA Package Insert==
-===Arixtra<sup>®</sup>===
+===Retavase<sup>®</sup>===
-'''| [[Fondaparinux indications and usage|Indications and Usage]]'''
+''' [[Reteplase indications and usage|Indications and Usage]]'''
-'''| [[Fondaparinux dosage and administration|Dosage and Administration]]'''
+'''| [[Reteplase dosage and administration|Dosage and Administration]]'''
-'''| [[Fondaparinux dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]'''
-'''| [[Fondaparinux contraindications|Contraindications]]'''
+'''| [[Reteplase contraindications|Contraindications]]'''
-'''| [[Fondaparinux warnings|Warnings and Precautions]]'''
+'''| [[Reteplase warnings and precautions|Warnings and Precautions]]'''
-'''| [[Fondaparinux adverse reactions|Adverse Reactions]]'''
+'''| [[Reteplase adverse reactions|Adverse Reactions]]'''
-'''| [[Fondaparinux drug interactions|Drug Interactions]]'''
+'''| [[Reteplase drug interactions|Drug Interactions]]'''
-'''| [[Fondaparinux use in specific populations|Use in Specific Populations]]'''
+'''| [[Reteplase use in specific populations|Use in Specific Populations]]'''
-'''| [[Fondaparinux overdosage|Overdosage]]'''
+'''| [[Reteplase overdosage|Overdosage]]'''
-'''| [[Fondaparinux description|Description]]'''
+'''| [[Reteplase description|Description]]'''
-'''| [[Fondaparinux clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Reteplase clinical pharmacology|Clinical Pharmacology]]'''
-'''| [[Fondaparinux nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Reteplase nonclinical toxicology|Nonclinical Toxicology]]'''
-'''| [[Fondaparinux clinical studies|Clinical Studies]]'''
+'''| [[Reteplase clinical studies|Clinical Studies]]'''
-'''| [[Fondaparinux how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Reteplase how supplied storage and handling|How Supplied/Storage and Handling]]'''
-'''| [[Fondaparinux patient counseling information|Patient Counseling Information]]'''
+'''| [[Reteplase patient counseling information|Patient Counseling Information]]'''
-'''| [[Fondaparinux labels and packages|Labels and Packages]]'''
+'''| [[Reteplase labels and packages|Labels and Packages]]'''
-[[image:fond.png]]
 ==Mechanism of Action==
-The antithrombotic activity of fondaparinux sodium is the result of [[antithrombin]] III (ATIII)-mediated selective inhibition of [[Factor Xa]]. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits [[thrombin ]]formation and thrombus development.
+Retavase® is a recombinant [[plasminogen activator]] which catalyzes the cleavage of endogenous [[plasminogen]] to generate [[plasmin]]. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in [[fibrinogen]] levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher =  | date =  |accessdate =  }}</ref>
-Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect[[ fibrinolytic ]]activity or bleeding time.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate = }}</ref>
 ==References==
 {{Reflist|2}}
-[[Category:Cardiovascular Drugs]]
+[[Category: cardiovascular Drugs]]
 [[Category:Drugs]]